Nuvilex, Inc. Pancreatic Cancer Trials Could Make "Cell-in-a-Box" Gold Standard
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 04/29/13 -- While many biotech and pharmaceutical companies are designing one drug after another to address specific health problems, Nuvilex, Inc. (OTCQB: NVLX) is using its own living cell encapsulation as a "one size fits all" type solution. The company is off to a great start at getting its "Cell-in-a-Box" technology on the map with its work in late stage, inoperable pancreatic cancer.
Nuvilex is headquartered in Silver Spring, Maryland, and while it is a small international biotech, the company has been delivering big results, and now it's preparing for an even bigger stage -- Phase III clinical trials. When it comes to pancreatic cancer, you can bet the NYSE's Eli Lilly and NASDAQ's Celgene Corp. are all too familiar with Nuvilex and its technology. Currently, Eli Lilly's drug Gemzar is the only drug to date approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer and the drug is considered the "gold standard" by the market. Eli Lilly introduced gemcitabine (Gemzar) back in 1996, and since that time, it has netted the drug's maker billions of dollars in sales.
Nipping at Eli Lilly's heels are both Celgene and Nuvilex, but of the three, the smallest of them all, has produced the best results in clinical trials using its living cell encapsulation. Nuvilex's "Cell-in-a-Box" is a process that forms a "platform" upon which treatments for many serious, debilitating, and even fatal diseases may be built. Some of these diseases include different types of cancer, diabetes, diseases for which stem cell therapies are being developed, and diseases caused by viruses.
The process uses living cells, and Nuvilex takes a very specific type of cell to address a specific problem a patient suffers from. Scientists then wrap up cells in a type of cellulose, forming essentially "cotton" capsules with live cells inside that form this "platform" or bundled miniature "house" of cells about the size of the head of a pin.
Continue reading this article at
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.
Contact:
Stock House Group
646-397-4020
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2013 - 12:30 Uhr
Sprache: Deutsch
News-ID 253777
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nuvilex, Inc. Pancreatic Cancer Trials Could Make "Cell-in-a-Box" Gold Standard"
steht unter der journalistisch-redaktionellen Verantwortung von
Nuvilex, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
